Mutation of Arabidopsis SMC4 Identifies Condensin As a Corepressor of Pericentromeric Transposons and Conditionally Expressed Genes
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
NCAPD3 Antibody (C-Term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP16786B
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 NCAPD3 Antibody (C-term) Affinity Purified Rabbit Polyclonal Antibody (Pab) Catalog # AP16786B Specification NCAPD3 Antibody (C-term) - Product Information Application WB,E Primary Accession P42695 Other Accession NP_056076.1 Reactivity Human Host Rabbit Clonality Polyclonal Isotype Rabbit Ig Calculated MW 168891 Antigen Region 1050-1078 NCAPD3 Antibody (C-term) - Additional Information NCAPD3 Antibody (C-term) (Cat. Gene ID 23310 #AP16786b) western blot analysis in K562 cell line lysates (35ug/lane).This Other Names Condensin-2 complex subunit D3, Non-SMC demonstrates the NCAPD3 antibody detected condensin II complex subunit D3, hCAP-D3, the NCAPD3 protein (arrow). NCAPD3, CAPD3, KIAA0056 Target/Specificity NCAPD3 Antibody (C-term) - Background This NCAPD3 antibody is generated from rabbits immunized with a KLH conjugated Condensin complexes I and II play essential synthetic peptide between 1050-1078 roles in amino acids from the C-terminal region of mitotic chromosome assembly and human NCAPD3. segregation. Both condensins contain 2 invariant structural maintenance of Dilution chromosome (SMC) WB~~1:1000 subunits, SMC2 (MIM 605576) and SMC4 (MIM 605575), but they contain Format different sets of non-SMC subunits. NCAPD3 is Purified polyclonal antibody supplied in PBS 1 of 3 non-SMC with 0.09% (W/V) sodium azide. This subunits that define condensin II (Ono et al., antibody is purified through a protein A 2003 [PubMed column, followed by peptide affinity 14532007]). purification. NCAPD3 Antibody (C-term) - References Storage Maintain refrigerated at 2-8°C for up to 2 Rose, J.E., et al. -
A Commercial Antibody to the Human Condensin II Subunit NCAPH2 Cross-Reacts with a SWI/SNF Complex Component
bioRxiv preprint doi: https://doi.org/10.1101/2020.11.07.372599; this version posted November 9, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY-ND 4.0 International license. A commercial antibody to the human condensin II subunit NCAPH2 cross-reacts with a SWI/SNF complex component Erin E. Cutts1*, Gillian C Taylor2*, Mercedes Pardo1, Lu Yu1, Jimi C Wills3, Jyoti S. Choudhary1, Alessandro Vannini1#, Andrew J Wood2# 1 Division of Structural Biology, The Institute of Cancer Research, London SW7 3RP, United Kingdom 2 MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, The University of Edinburgh, Edinburgh, EH4 2XU, UK. 3 Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, EH4 2XU, UK. * Equal contribution # correspondence to: [email protected], [email protected]. Summary Condensin complexes compact and disentangle chromosomes in preparation for cell division. Commercially available antibodies raised against condensin subunits have been widely used to characterise their cellular interactome. Here we have assessed the specificity of a polyclonal antibody (Bethyl A302- 276A) that is commonly used as a probe for NCAPH2, the kleisin subunit of condensin II, in mammalian cells. We find that, in addition to its intended target, this antibody cross-reacts with one or more components of the SWI/SNF family of chromatin remodelling complexes in an NCAPH2- independent manner. This cross-reactivity with an abundant chromatin- associated factor is likely to affect the interpretation of protein and chromatin immunoprecipitation experiments that make use of this antibody probe. -
Condensation of Prometaphase Chromo-Somes
Condensation of Prometaphase Chromo- somes D'Eustachio, P., Matthews, L., Orlic-Milacic, M. European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University. The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of Creative Commons Attribution 4.0 Inter- national (CC BY 4.0) License. For more information see our license. 09/03/2019 Introduction Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross- referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics research- ers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioin- formaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways. The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program). Literature references Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway ana- lysis: a high-performance in-memory approach. BMC bioinformatics, 18, 142. ↗ Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. -
Three Optimized Workflows for Cpg Island Methylation Profiling
APPLICATION NOTE Three Optimized Workflows for CpG Island Methylation Profiling Three Optimized Workflows for CpG Island Methylation Profiling DNA methylation is involved in the Discovery regulation of many cellular processes SOLiD™ Do you know your candidate gene? including X chromosome inactivation, No System chromosome stability, chromatin structure, Yes embryonic development, and transcription. Validation/Screening with Capillary Electrophoresis Do you know your candidate region or In mammals only the 5' carbons of the methylation state of that region? cytosines adjacent to guanines (CpG Yes No dinucleotides: cytosine-phospho-guanine) MSMSA Bisulfite Conversion Bisulfite Conversion are substrates for DNA methylation. (MethylSEQr™ Kit) (MethylSEQr™ Kit) Importance of CpG Islands Are there a high number Bisulfite Specific (BSP) CpG islands are 300−3000 base pair of poly T or A, or large Primer Design fragment size (>300 bps)? (Methyl Primer® Express) stretches of DNA that are CG rich, and are often found within unmethylated Yes No regions of promoters. Profiling of CpG Clone based Sequencing Direct PCR Sequencing island methylation indicates that some Fluorescent BSP PCR genes are more frequently methylated Bisulfite Specific (BSP) Primer Design Bisulfite Specific (BSP) Primer Design Data Analysis (Methyl Primer® Express) (Methyl Primer® Express) than others [1]. Hence, CpG islands play a (GeneMapper® Software v. 4.0) critical role in regulating gene expression. CpG islands found outside promoter BSP PCR BSP PCR Identification of a candidate region or the No regions are commonly methylated, and methylation state of Yes that region? are believed to be responsible for silencing Cloning Yes transcription of repetitive sequences Cycle Sequencing Direct PCR Cycle Sequencing Are there a high number and parasitic sequence elements, such of poly T or A, or large No as viral DNA. -
DNA Methylation Analysis: Choosing the Right Method
biology Review DNA Methylation Analysis: Choosing the Right Method Sergey Kurdyukov 1,* and Martyn Bullock 2 Received: 8 July 2015; Accepted: 22 December 2015; Published: 6 January 2016 Academic Editor: Melanie Ehrlich 1 Genomics Core facility, Kolling Institute of Medical Research, University of Sydney, Sydney 2065, Australia 2 Cancer Genetics Laboratory, Kolling Institute of Medical Research, University of Sydney, Sydney 2065, Australia; [email protected] * Correspondence: [email protected]; Tel.: +61-299-264-756 Abstract: In the burgeoning field of epigenetics, there are several methods available to determine the methylation status of DNA samples. However, choosing the method that is best suited to answering a particular biological question still proves to be a difficult task. This review aims to provide biologists, particularly those new to the field of epigenetics, with a simple algorithm to help guide them in the selection of the most appropriate assay to meet their research needs. First of all, we have separated all methods into two categories: those that are used for: (1) the discovery of unknown epigenetic changes; and (2) the assessment of DNA methylation within particular regulatory regions/genes of interest. The techniques are then scrutinized and ranked according to their robustness, high throughput capabilities and cost. This review includes the majority of methods available to date, but with a particular focus on commercially available kits or other simple and straightforward solutions that have proven to be useful. Keywords: DNA methylation; 5-methylcytosine; CpG islands; epigenetics; next generation sequencing 1. Introduction DNA methylation in vertebrates is characterized by the addition of a methyl or hydroxymethyl group to the C5 position of cytosine, which occurs mainly in the context of CG dinucleotides. -
Interactome Analyses Revealed That the U1 Snrnp Machinery Overlaps Extensively with the RNAP II Machinery and Contains Multiple
www.nature.com/scientificreports OPEN Interactome analyses revealed that the U1 snRNP machinery overlaps extensively with the RNAP II Received: 12 April 2018 Accepted: 24 May 2018 machinery and contains multiple Published: xx xx xxxx ALS/SMA-causative proteins Binkai Chi1, Jeremy D. O’Connell1,2, Tomohiro Yamazaki1, Jaya Gangopadhyay1, Steven P. Gygi1 & Robin Reed1 Mutations in multiple RNA/DNA binding proteins cause Amyotrophic Lateral Sclerosis (ALS). Included among these are the three members of the FET family (FUS, EWSR1 and TAF15) and the structurally similar MATR3. Here, we characterized the interactomes of these four proteins, revealing that they largely have unique interactors, but share in common an association with U1 snRNP. The latter observation led us to analyze the interactome of the U1 snRNP machinery. Surprisingly, this analysis revealed the interactome contains ~220 components, and of these, >200 are shared with the RNA polymerase II (RNAP II) machinery. Among the shared components are multiple ALS and Spinal muscular Atrophy (SMA)-causative proteins and numerous discrete complexes, including the SMN complex, transcription factor complexes, and RNA processing complexes. Together, our data indicate that the RNAP II/U1 snRNP machinery functions in a wide variety of molecular pathways, and these pathways are candidates for playing roles in ALS/SMA pathogenesis. Te neurodegenerative disease Amyotrophic Lateral Sclerosis (ALS) has no known treatment, and elucidation of disease mechanisms is urgently needed. Tis problem has been especially daunting, as mutations in greater than 30 genes are ALS-causative, and these genes function in numerous cellular pathways1. Tese include mitophagy, autophagy, cytoskeletal dynamics, vesicle transport, DNA damage repair, RNA dysfunction, apoptosis, and pro- tein aggregation2–6. -
High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early-Onset and Familial Risk Breast Cancer Patients
Author Manuscript Published OnlineFirst on June 7, 2019; DOI: 10.1158/1078-0432.CCR-18-2423 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. High-Resolution Bisulfite-Sequencing of Peripheral Blood DNA Methylation in Early- Onset and Familial Risk Breast Cancer Patients Justin Chen1*, Maria K. Haanpää2*, Joshua J. Gruber1,2, Natalie Jäger1, James M. Ford1,2ǂ, and Michael P. Snyder1ǂ 1Department of Genetics 2Department of Medicine, Oncology Division Stanford University, Stanford, CA 94305, USA. * These authors contributed equally to this work. ǂ Co-corresponding authors Running Title: DNA Methylation and High-Risk Breast Cancer Keywords: DNA Methylation; Breast Cancer; Epigenetics; Cancer Predisposition; Allelic Methylation Additional Information: Financial Support: This work used the Genome Sequencing Service Center by Stanford Center for Genomics and Personalized Medicine Sequencing Center, supported by the grant award NIH S10OD020141. MKH is supported by grants from Sigrid Juselius Foundation, Orion Research Foundation, Päivikki ja Sakari Sohlberg Foundation and Instrumentarium Science Foundation. JJG was supported by fellowships from the Jane Coffin Childs Memorial Fund for Medical Research, Stanford Cancer Institute and Susan G. Komen Foundation, as well as funding from ASCO, the Conquer Cancer Foundation and the Breast Cancer Research Foundation. NJ was supported by an EMBO Long-Term Fellowship (ALTF 325-2014). JMF is supported by the BRCA Foundation and the Breast Cancer Research Foundation. MPS is supported by grants from the NIH including a Centers of Excellence in Genomic Science award (5P50HG00773504). Correspondence: Michael P. Snyder James M. Ford Department of Genetics 269 Campus Dr. Stanford University School of Medicine CCSR Room 1115 300 Pasteur Dr. -
A Yeast Phenomic Model for the Influence of Warburg Metabolism on Genetic Buffering of Doxorubicin Sean M
Santos and Hartman Cancer & Metabolism (2019) 7:9 https://doi.org/10.1186/s40170-019-0201-3 RESEARCH Open Access A yeast phenomic model for the influence of Warburg metabolism on genetic buffering of doxorubicin Sean M. Santos and John L. Hartman IV* Abstract Background: The influence of the Warburg phenomenon on chemotherapy response is unknown. Saccharomyces cerevisiae mimics the Warburg effect, repressing respiration in the presence of adequate glucose. Yeast phenomic experiments were conducted to assess potential influences of Warburg metabolism on gene-drug interaction underlying the cellular response to doxorubicin. Homologous genes from yeast phenomic and cancer pharmacogenomics data were analyzed to infer evolutionary conservation of gene-drug interaction and predict therapeutic relevance. Methods: Cell proliferation phenotypes (CPPs) of the yeast gene knockout/knockdown library were measured by quantitative high-throughput cell array phenotyping (Q-HTCP), treating with escalating doxorubicin concentrations under conditions of respiratory or glycolytic metabolism. Doxorubicin-gene interaction was quantified by departure of CPPs observed for the doxorubicin-treated mutant strain from that expected based on an interaction model. Recursive expectation-maximization clustering (REMc) and Gene Ontology (GO)-based analyses of interactions identified functional biological modules that differentially buffer or promote doxorubicin cytotoxicity with respect to Warburg metabolism. Yeast phenomic and cancer pharmacogenomics data were integrated to predict differential gene expression causally influencing doxorubicin anti-tumor efficacy. Results: Yeast compromised for genes functioning in chromatin organization, and several other cellular processes are more resistant to doxorubicin under glycolytic conditions. Thus, the Warburg transition appears to alleviate requirements for cellular functions that buffer doxorubicin cytotoxicity in a respiratory context. -
Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeuti
cancers Article Identification and Validation of an Immune-Associated RNA-Binding Proteins Signature to Predict Clinical Outcomes and Therapeutic Responses in Glioma Patients Ruotong Tian 1,† , Yimin Li 2,†, Qian Liu 1 and Minfeng Shu 1,* 1 Department of Pharmacology, School of Basic Medical Sciences, Shanghai Medical College, Fudan University, No.131 Dong’an Road, Xuhui District, Shanghai 200032, China; [email protected] (R.T.); [email protected] (Q.L.) 2 Department of Pathology, Fudan University Shanghai Cancer Center, No.270 Dong’an Road, Xuhui District, Shanghai 200032, China; [email protected] * Correspondence: [email protected]; Tel.: +86-21-54237380-2 † These authors contributed equally to this work. Simple Summary: Both of tumor-infiltrating immune cells and the RNA-binding proteins (RBPs) that are able to mediate immune infiltration contribute to the prognosis of patients with glioma. However, immune-associated RBPs in glioma remain unexplored. In this study, we developed a method to identify RBPs associated with immune infiltration in glioma and 216 RBPs were defined as immune- associated RBPs. Among them, eight RBPs were selected to construct a risk signature that proved to be a novel and independent prognostic factor. Higher risk scores meant worse overall survival and higher expression of human leukocyte antigen and immune checkpoints. Additionally, analyses of pathway enrichment, somatic mutation, copy number variations, and immuno-/chemotherapeutic Citation: Tian, R.; Li, Y.; Liu, Q.; Shu, response prediction were performed to evaluate the differences between high- and low-risk groups. M. Identification and Validation of an Generally, we demonstrated an eight immune-associated RBPs prognostic signature that was valuable Immune-Associated RNA-Binding in predicting the survival of glioma patients and directing immunotherapy and chemotherapy. -
HITTING the MARK in CANCER EPIGENETICS Research in Cancer Epigenetics Is Advancing Rapidly
HITTING THE MARK IN CANCER EPIGENETICS Research in cancer epigenetics is advancing rapidly. Here’s an overview of the tools and methods scientists use to drive progress in the field. For by CUSTOM MEDIA ADVERTISEMENT FEATURE ADVERTISEMENT FEATURE says. “We usually put these cytosine ring — is the best look and behave. Illumina’s Andrew Feber, a cancer patients on a watch and understood epigenetic marker methylation array covers geneticist at UCL Cancer HITTING THE MARK wait scheme. We could have today. Methylation typically 850,000 sites on the Institute in London, is one spared her all that therapy.” silences gene transcription genome, and analyses with of those scientists. He aims Pfister’s experience in patterns that are it, he says, “are sufficient to find epigenetic traces IN CANCER EPIGENETICS illustrates the growing characteristic to specific cell to capture the cancer cell’s of bladder cancer in urine, potential of genomic types and tissues. But when basic identity”. an endeavour he says is RESEARCH IN CANCER EPIGENETICS IS ADVANCING RAPIDLY. Here’s an overview of the tools technologies in epigenetics to it silences tumour suppressor Esteller points out that particularly well suited to and methods scientists use to drive progress in the field. contribute to understanding, genes, cancer may appear. methylation arrays have sequencing since it can diagnosing and treating The first epigenetic many positive aspects, such read the often fragmented cancer. Epigenetic technologies — methylation as low-cost and amenability arrangements of DNA modifications to DNA and arrays — emerged about 15 to formalin-fixed, paraffin- letters in liquid specimens. n 2013 Stefan Pfister, RNA regulate how and when years ago with the launch embedded tissue samples. -